Loading...
•
Jun 30, 2023
Allovir Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
AlloVir reported its Q2 2023 financial results, highlighting the progress of its allogeneic, off-the-shelf virus-specific T cell (VST) programs, including posoleucel. The company's three Phase 3 global registrational trials for posoleucel are ongoing, with data expected in the second half of 2024. AlloVir's cash position is expected to fund operations into 2025, through anticipated data readouts from the posoleucel Phase 3 trials.
Three Phase 3 global registrational trials of posoleucel continue to enroll, with data anticipated in the second half of 2024.
Positive data from the Phase 2 trial of posoleucel for treatment of BK viremia in kidney transplant recipients was presented at the American Transplant Congress (ATC 2023).
ALVR106 completed enrollment in the dose-escalation (Part A) portion of the Phase 1b/2a clinical trial.
A recent stock offering extends cash runway through Phase 3 data readouts and into 2025.
Forward Guidance
For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...